Related Experiment Video
Updated: Feb 12, 2026

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
Published on: June 13, 2018
Increasing genomic instability during cancer therapy in a patient with Li-Fraumeni syndrome
Nadine Schuler1, Jan Palm1, Sabine Schmitz2
1Department of Radiation Oncology, Saarland University, D-66421 Homburg/Saar, Germany.
Background:
Li-Fraumeni syndrome (LFS) is a cancer predisposition disorder characterized by germline mutations of the p53 tumor-suppressor gene. In response to DNA damage, p53 stimulates protective cellular processes including cell-cycle arrest and apoptosis to prevent aberrant cell proliferation. Current cancer therapies involve agents that damage DNA, which also affect non-cancerous hematopoietic stem/progenitor cells. Here, we report on a child with LFS who developed genomic instability during craniospinal irradiation for metastatic choroid plexus carcinoma (CPC).
Case Presentation:
This previously healthy 4-year-old boy presented with parieto-temporal brain tumor, diagnosed as CPC grade-3. Screening for cancer-predisposing syndrome revealed heterozygous p53 germline mutation, leading to LFS diagnosis. After tumour resection and systemic chemotherapy, entire craniospinal axis was irradiated due to leptomeningeal seeding, resulting in disease stabilization for nearly 12 months. Blood lymphocytes of LFS patient (p53-deficient) and age-matched tumor-children (p53-proficient) were collected before, during and after craniospinal irradiation and compared with asymptomatic carriers for identical p53 mutation, not exposed to DNA-damaging treatment. In p53-deficient lymphocytes of LFS patient radiation-induced DNA damage failed to induce cell-cycle arrest or apoptosis. Although DNA repair capacity was not impaired, p53-deficient blood lymphocytes of LFS patient showed significant accumulation of 53BP1-foci during and even several months after irradiation, reflecting persistent DNA damage. Electron microscopy revealed DNA abnormalities ranging from simple unrepaired lesions to chromosomal abnormalities. Metaphase spreads of p53-deficient lymphocytes explored by mFISH revealed high amounts of complex chromosomal aberrations after craniospinal irradiation.
Conclusions:
Tumor suppressor p53 plays a central role in maintaining genomic stability by promoting cell-cycle checkpoints and apoptosis. Here, we demonstrate that a patient with LFS receiving craniospinal irradiation including large volumes of bone marrow developed progressive genomic instability of the hematopoietic system. During DNA-damaging radiotherapy, genome-stabilizing mechanisms in proliferating stem/progenitor cells are perturbed by p53 deficiency, increasing the risk of cancer initiation and progression.
Insights
Li-Fraumeni syndrome (LFS) patients with p53 deficiency experience genomic instability during DNA-damaging cancer therapy. This p53 deficiency impairs DNA repair, increasing cancer risk.
Area of Science:
- Oncology
- Genetics
- Cancer Biology
Background:
- Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition caused by germline mutations in the p53 tumor-suppressor gene.
- The p53 protein is crucial for cellular responses to DNA damage, including cell-cycle arrest and apoptosis, preventing uncontrolled cell growth.
Observation:
- A 4-year-old boy with LFS and metastatic choroid plexus carcinoma (CPC) developed genomic instability during craniospinal irradiation.
- p53-deficient lymphocytes from the LFS patient failed to arrest cell cycle or undergo apoptosis following radiation exposure.
- Persistent DNA damage, evidenced by 53BP1 foci and chromosomal abnormalities, was observed in the LFS patient's lymphocytes post-irradiation.
Findings:
- Craniospinal irradiation in an LFS patient led to progressive genomic instability in the hematopoietic system.
- p53 deficiency perturbs genome-stabilizing mechanisms in proliferating stem and progenitor cells during DNA-damaging radiotherapy.
- Despite intact DNA repair capacity, p53-deficient cells accumulated significant unrepaired DNA damage and chromosomal aberrations.
Implications:
- p53 deficiency compromises the cellular response to genotoxic cancer therapies, increasing the risk of secondary malignancies.
- Understanding these mechanisms is crucial for developing safer and more effective cancer treatments for LFS patients.
- This study highlights the critical role of p53 in maintaining genomic integrity during cancer therapy.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Genomics
Microtubule Instability
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Gene Therapy